Avadel (AVDL) Gets 26% Boost on Takeover Bid

We recently published 10 Market Movers That Made Millionaires in a Week. Avadel Pharmaceuticals plc (NASDAQ:AVDL) is one of the best-performing stocks of the past trading week.

Avadel jumped by 26.06 percent week-on-week as investors loaded up portfolios after receiving a new takeover interest from a new pharmaceutical giant.

Last Friday, Avadel Pharmaceuticals plc (NASDAQ:AVDL) soared to as much as $23.57—its highest price in more than a decade—before ending the day just up by 22.45 percent at $23.56 apiece, following announcements that it received a new acquisition interest from H Lundbeck A/S to buy its shares at a price of $23 apiece.

The total price was significantly higher than Alkermes’ bid of $20 apiece.

Under Lundbeck’s offer, it would acquire the shares for $21 in cash and non-transferrable contingent value rights (CVR) amounting to $2 upon the achievement of two annual sales milestones for Lumryz and valiloxybate.

Avadel (AVDL) Gets 26% Boost on Takeover Bid

A dose bottle of the medication is in the medical tech’s hand

Meanwhile, Alkermes sought to buy the shares for $18.50 per share, and a CVR of $1.50 contingent upon final approval of the Food and Drug Administration of Lumryz.

Despite a definitive agreement already signed between Avadel Pharmaceuticals plc (NASDAQ:AVDL) and Alkermes, the former said that its board of directors deemed Lundbeck’s proposal to be superior.

Avadel cannot break its agreement with Alkermes, but it is allowed to talk and share information with another prospective buyer.

While we acknowledge the risk and potential of AVDL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AVDL and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.